目的:评价风眩宁方联合倍他司汀治疗周围性眩晕的临床疗效。

方法:前瞻性纳入2021年7月-2023年1月在上海市中西医结合医院脑病科接受治疗的周围性眩晕患者 70 例,采用随机数字表法分为倍他司汀组(35 例)和风眩宁方联合倍他司汀组(35 例)。风眩宁方联合倍他司汀组患者接受风眩宁方联合倍他司汀治疗,倍他司汀组患者仅接受倍他司汀治疗。比较2组患者的症状评分、脑干听觉诱发电位(brainstem auditory evoked potential,BAEP)、前庭功能、血液流变学和治疗相关不良反应。

结果:治疗前,2 组患者的头晕目眩、倦怠无力、耳鸣耳聋、恶心呕吐、出汗异常和眼震评分以及眩晕症状总评分的差异均无统计学意义(P>0.05)。治疗后,2组患者的头晕目眩、倦怠无力、耳鸣耳聋、恶心呕吐、出汗异常和眼震评分以及眩晕症状总评分均低于治疗前( P<0.05)。治疗后,风眩宁方联合倍他司汀组患者的头晕目眩、倦怠无力、耳鸣耳聋、恶心呕吐、出汗异常和眼震评分以及眩晕症状总评分均低于倍他司汀组( P<0.05)。风眩宁方联合倍他司汀组患者的 BAEP、变温试验、眼震电图和甩头试验(head thrust test,HIT)检查结果异常率均显著低于倍他司汀组( P<0.05),不良反应发生率[3/35(8.57%)]也显著低于倍他司汀组[34.29%(12/35)(P<0.05)。治疗后,风眩宁方联合倍他司汀组患者的血浆黏度、全血低切黏度、全血高切黏度和红细胞聚集指数均显著低于倍他司汀组(P<0.05)。

结论:与单用倍他司汀相比,风眩宁方联合倍他司汀治疗周围性眩晕的疗效更佳,值得临床推广应用。

Objective: To observe the clinical efect of Fengxuanning prescription combined with betahistine in the treatment of peripheral vertigo.

Methods: A prospective study included 70 patients with peripheral vertigo who received treatment in the Department of Neurology, Shanghai TCM-Integrated Hospital from July 2021 to January 2023. They were randomly divided into betahistine group (35 cases,receiving betahistine alone)and Fengxuanning prescription combined with betahistine group (35 cases,receiving Fengxuanning prescription combined with betahistine) using a random number table method. The symptom scores, brainstem auditory evoked potential (BAEP) vestibular finction, hemorheology and treatment-related adverse reactions between the two groups were compared.

Results: Before treatment,there were no significant differences in symptoms such as dizziness, fatigue, weakness, tinnitus, deafness,nausea and vomiting,and abnormal sweating/nystagmus scores as well as the comprehensive symptom score between the two groups (all P>005). After treatment, the dizziness, fatigue, weakness, tinnitus deafness, nausea and vomiting,and abnormal sweating/nystagmus scores as well as the comprehensive symptom scores of the two groups were lower than those before treatment (all P<0.05). The dizziness,fatigue, weakness,tinnitus, deaness, nausea and vomiting and abnormal sweating/nystagmus scores as well as the comprehensive symptom score of the Fengxuanning prescription combined with betahistine group were lower than those of the betahistine group (all P<005). The abnormal rates of BAEP, caloric test electronystagmography and head thrust test (HIT results of the Fengxuanning prescription combined with betahistine group were lower than those of the betastatin group (all P<005), and the incidence of adversereactions was 8.57% (3/35, which was lower than 34.29% (12/35) of the betahistine group(P<0.05). The plasma viscosity, whole blood low and high shear viscosities, and red blood cell aggregation index of the Fengxuanning prescription combined with betahistine group were lower than those of the betastatin group(all P<0.05).

Conclusion: Compared with using betahistine alone, Fengxuanning prescription combined with betahistine has better effects in the treatment of peripheral vertigo.